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Abstract
Purpose—Aggressive pancreatic cancer is commonly associated with a dense desmoplastic 
stroma, which forms a protective niche for cancer cells. The objective of the study was to 
determine the functions of tissue transglutaminase (TG2), a Ca2+-dependent enzyme which 
crosslinks proteins through transamidation and is abundantly expressed by pancreatic cancer cells 
in the pancreatic stroma.
Experimental Design—Orthotopic pancreatic xenografts and co-culture systems tested the 
mechanisms by which the enzyme modulates tumor-stroma interactions.
Results—We show that TG2 secreted by cancer cells effectively molds the stroma by 
crosslinking collagen, which in turn activates fibroblasts and stimulates their proliferation. The 
stiff fibrotic stromal reaction conveys mechanical cues to cancer cells leading to activation of the 
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YAP/TAZ transcription factors, promoting cell proliferation and tumor growth. Stable knockdown 
of TG2 in pancreatic cancer cells led to decreased size of pancreatic xenografts.
Conclusions—Taken together, our results demonstrate that TG2 secreted in the tumor 
microenvironment orchestrates the crosstalk between cancer cells and stroma fundamentally 
impacting tumor growth. Our study supports TG2 inhibition in the pancreatic stroma as a novel 
strategy to block pancreatic cancer progression.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) is the fourth cause of cancer death (1). With the 
currently available treatment, the majority of patients succumb to disease, resistance to 
chemotherapy and radiation having been implicated as pivotal obstacles (2). A hallmark of 
pancreatic tumors is the dense desmoplastic stroma (DS) composed of myofibroblasts and 
stellate cells which secrete collagens and other matrix proteins that serve as a scaffold on 
which tumor cells proliferate (3–5). These stromal components are highly responsive to 
cytokines (TGF-β) and growth factors (PDGFs, FGFs, sonic hedgehog) abundantly secreted 
in the tumor microenvironment (TME) (4–7). The stroma, believed to protect PDA cells 
from environmental stress, is hypovascular, hypoxic, and presumably less permeable to 
chemotherapy (4, 5, 8). In support of the latter concept, a recent study using clinical PDA 
specimens demonstrated that the delivery of gemcitabine into human pancreatic tumors is 
highly heterogenous and strongly correlated with the existing stromal reaction (9, 10). 
However, two other recent reports have suggested that some components of the stroma may 
play a reverse role, by restraining cancer cell invasion and preventing tumor metastasis (11, 
12). The latter studies used analyses in genetically engineered PDA mouse models that may 
not faithfully mirror the desmoplastic reaction of human tumors. The conflicting outcomes 
of previous studies (8, 12) coupled with the continued lack of success treating this 
recalcitrant disease, underscore the complex interplay between the diverse components of 
pancreatic tumors and the inherent limitations of existing experimental models to study and 
replicate the diverse traits of the human disease (13). The data presented here highlight the 
crosstalk between cancer and stromal cells mediated by tissue transglutaminase (TG2) and 
the significance of the crosslinking reaction mediated by this enzyme in the matrix to PDA 
progression.
TG2 is a TGF-β inducible protein (14) secreted in the extracellular milieu which mediates 
the transfer of acyl groups between glutamine and lysine residues, causing protein 
crosslinking (15). Highly expressed in pancreatic cancer cells and tumors, TG2 was reported 
to activate NF-κB orchestrated survival mechanisms and to contribute to chemotherapy 
resistance, independently of its enzymatic function (16, 17). Whether and how TG2 
promotes pancreatic tumor growth remains not clear. Based on the knowledge that the 
enzyme is secreted and acts as a potent crosslinking factor for collagens and matrix proteins 
(18), and that the enzymatic function of TG2 is augmented in the extracellular matrix (ECM) 
by factors such as hypoxia and tissue injury (19), we hypothesized that TG2 secreted by 
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pancreatic cancer cells into the tumor milieu alters the composition of the stroma, which in 
turn augments oncogenic signaling in cancer cells facilitating tumor progression.
By using pancreatic orthotopic xenografts we demonstrate that TG2 knockdown in PDA 
cells inhibits tumor formation and growth. We show that TG2 is enzymatically active in 
pancreatic cells and tumors, and is secreted in the TME where it crosslinks collagen and 
stimulates the proliferation of myofibroblasts. The stroma enriched in crosslinked collagen 
and fibroblasts activates the Yes-associated protein (YAP) and transcriptional coactivator 
with PDZ-binding motif (TAZ) transcription factors in cancer cells and promotes cell 
proliferation. This is the first report describing the role of TG2 in the pancreatic DS and 
demonstrating its role in the activation of YAP/TAZ transcription factors in cancer cells. 
Taken together our data support that by facilitating the crosstalk between cancer and stromal 
cells, TG2 promotes PDA progression.
Materials and Methods
Chemicals and reagents
Antibodies for TG2 (NeoMarkers, Fremont, CA), YAP1 (Abnova, Walnut, CA), p-YAP 
(Ser127) and YAP/TAZ (Cell Signaling Technology, Danvers, MA), and GAPDH (Meridian 
Life Science, Inc., Memphis, TN) were used for western blotting. Recombinant 
enzymatically active or mutant (C277S) TG2 were purified as previously described (20). 
Unless stated otherwise, all reagents were from Sigma-Aldrich (St Louis, MO, USA).
Cell culture
AsPC1, BxPC3, and Paca2 cells were obtained from the American Type Culture Collection 
(Rockville, MD), human pancreatic normal epithelial (HPNE) and Panc1 cells were a gift 
from Prof. Murray Korc (21). The normal human dermal fibroblasts (NHF544) were 
provided by Dr. Dan Spandau, and GFP-expressing neonatal dermal fibroblasts (GFP-
HNDFs) were purchased from Angioproteomie (Boston, MA). Human pancreatic stellate 
cells (hPSCs) were from ScienCell Research Laboratories (Carlsbad, CA), and the 
mesothelial cell line, LP9, was from the NIA Aging Cell Repository (Camden, NJ). All cell 
lines were tested for mycoplasma and authenticated by the IUSCC In Vivo Therapeutics 
Core. AsPC1 and BxPC3 cells were cultured in RPMI 1640 medium (Cellgro, Manassas, 
VA) supplemented with 10% fetal bovine serum (FBS) (Cellgro) and 1% antibiotics. Panc1, 
Paca2, NHF544, GFP-HNDFs, LP9, and hPSCs were grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Cellgro) supplemented with 10% FBS and 1% antibiotics. Cells were 
grown at 37°C under 5% CO2. Conditioned media (CM) was collected after 24 hour 
incubation of 5×105 PDA cells in serum free RPMI media. Co-culture experimental details 
are provided in Supplemental Materials (SM).
Immunohistochemistry (IHC) was performed as previously described (22) (see SM).
Cell transfection
TG2 was stably knocked down in AsPC1 and Panc1 cells by transducing MISSION® 
shRNA Lentiviral Transduction Particles (Sigma), containing short hairpin RNAs (shRNA) 
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targeting TG2 (shTG2) in the presence of polybrene (8μg/mL). As control (shCtrl), cells 
were transduced with MISSION® pLKO.1-puro Empty Vector control Transfection 
Particles (Sigma). Both shCtrl and shTG2 particles were transduced at 2.5 multiplicity of 
infection. Pooled stable clones were collected after selection with puromycin at 1 μg/ml 
concentration, and TG2 knockdown was verified by western blotting. Transient transfection 
of short interfering RNA (siRNA) used sequences targeting YAP and TAZ (Santa Cruz) and 
Lipofectamine® 3000 (Life technologies, Carlsbad, CA). siGENOME™ Control Pool 
(Dharmacon, Lafayette, CO) was use as control.
Western Blot Analysis followed a standard protocol (see SM).
Orthotopic Pancreatic Xenografts
1.5×105 AsPC1 and Panc1 cells, stably transfected with shTG2 or shCtrl were injected into 
the pancreatic tail of 7–8 weeks old female nude mice (Harlan, Indianapolis, IN) using a 
27.5 gauge needle under isoflurane anesthesia. Three (Panc1 cells) or 4 weeks (AsPC1 cells) 
after injection, mice were euthanized and tumors were weighted and measured. Tumor 
volumes were calculated as 4/3*π*(L/2)*(W/2)*(H/2); where L is length, W, width, and H, 
height. Metastatic implants were counted. Animal experiments were approved by the IU 
Animal Care and Use Committee, in compliance with federal regulations.
Immunofluorescence (IF) used antibodies for TG2 (Neomarkers), α-SMA (Sigma), 
collagen 1 (Abcam), and YAP/TAZ (Cell Signaling). To detect matrix-bound TG2, cells 
were not permeabilized before incubation with the TG2 antibody, as previously described 
(23). Procedures are detailed in SM.
Proliferation Assays were performed as described in SM.
Reporter Assay
To measure YAP/TAZ transcriptional activity, PDA cells were transfected with pGal4-
TEAD4, pGal4-Luciferase, and pTK-Renilla at a ratio of 1:10:1 using DreamFect (Oz 
Biosciences, Inc., San Diego, CA). Plasmids were a gift from Dr. Clark Wells (IUSCC) (24). 
The Dual-Luciferase® Assay System kit (Promega, Madison, WI) determined TEAD4 
reporter activity after 48 hours of transfection. To control for transfection efficiency, the 
luciferase activity was normalized to renilla.
Reverse Transcription PCR (RT-PCR) and Quantitative Real-Time PCR (qRT-PCR) 
procedures are described in SM.
Collagen Crosslinking
Collagen 1 solution (StemCell Technologies, Vancouver, BC) was treated with TG2 (Sigma) 
in the presence of 1 mM DTT, 5 mM CaCl2, and 100 mM Tris-HCl (pH 8.0), as previously 
described (25) for 1.5 hours at 37°C.
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Picrosirius Red (PSR) Staining
Paraffin-embedded slides were incubated with PSR solution containing 0.1% of Direct red 
80 powder (Sigma) dissolved in picric acid (Sigma) for 1 hour. Nuclei were counterstained 
with hematoxylin. The slides were washed in 0.5% glacial acetic acid and dehydrated in 
ethanol and xylene. Imaging with circular polarizing light used an inverted Nikon Diaphot 
200 microscope (Nikon, Melville, NY). The proportion of differently colored collagen fibers 
was quantified with MetaMorph (Molecular Devices, see SM) (26).
Soluble Collagen Assay
Soluble collagen in xenografts (n=6 per group) was determined by using the Sircol™ 
Soluble Collagen Assay kit (Biocolor Life Science Assays, Northern Ireland, see SM).
TG2 Activity
PDA cells and fibroblasts were incubated with 500 μM 5-(Biotinamido) pentylamine (5-BP) 
(ThermoScientific) for 1 hour at 37°C. After fixing in methanol, slides were incubated with 
Alexa Fluor® 647 streptavidin (Life Technologies) for 1 hour. To assay in situ activity of 
TG2 in tumor tissue, 10 μm cryosections were incubated at 37°C in a buffer containing 5 
mM CaCl2, 100 mM Tris-HCl (pH 8.0), in the presence or absence of 1 mM DTT, and 0.001 
mM T26 or T26QN (negative control), as described (27–29). As another negative control, 5 
mM EDTA was added to the buffer. Imaging used a LSM 510 META confocal microscope 
(Carl Zeiss, Inc.) under UV excitation.
Statistical analysis
Student’s t test compared measurements. P < 0.05 was significant.
Results
TG2 is abundantly expressed and enzymatically active in PDA cells and stroma
We used immunohistochemistry (IHC) to measure TG2 expression and cellular localization 
in PDA specimens and in normal pancreas. Patient characteristics are presented in SM 
(Supplementary Table 1). No immunostaining was recorded in the stroma of normal 
pancreas (n=3), and faint (1+) staining was noted in normal ducts. In contrast, strong (2+ to 
3+) TG2 cytoplasmic immunostaining was recorded in 36 out of 52 (69%) PDA specimens, 
supporting that TG2 expression is increased in PDA compared to normal duct epithelium. 
TG2 immunostaining was also recorded in the stroma of 44 out of 52 specimens (84%, 
Figure 1A), involving both the cellular (fibroblasts) and extracellular compartments. To 
determine whether TG2 was enzymatically active in the stroma, 20 additional tumors 
identified through the IUSCC Tissue Bank as PDA specimens associated with significant 
desmoplasia were stained for TG2 and for isopeptide, a covalent bond resulting from TG2 
mediated transamidation. Concordant strong (2+ to 3+) TG2 and isopeptide staining were 
recorded in 19 out of 20 specimens (Figure 1A), supporting that TG2 is expressed and active 
in the pancreatic DS. Isopeptide staining was detectable in the matrix and the basal 
membrane.
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TG2 expression levels in cell lysates and CM from PDA, HPNE, stellate cells, and 
fibroblasts were examined by using western blotting. Abundant TG2 expression was 
detected in BxPC3 and AsPC1 cells and in the conditioned media (CM), confirming that it is 
secreted by PDA cells (Figures 1B). TG2 expression was detectable in HPNE cells but lower 
than in most cancer cell lines. Immunofluorescence (IF) determined TG2 cellular 
localization and enzymatic activity by measuring incorporation of 5-(Biotinamido) 
pentylamine (5-BP) and FITC-labeled T26 peptide, known TG2 substrates (Figure 1C and 
Supplementary Figure 1). TG2 was expressed in the cytosol and the plasma membrane of 
AsPC1 and Panc1 cells, and its enzymatic activity was detectable in the cytoplasm of both 
cell types. In contrast, TG2 was present, but was enzymatically inactive in fibroblasts 
(Figure 1C) and in LP9 normal mesothelial cells (Supplementary Figure 1B), suggesting that 
the enzymatic activity may be differentially regulated in cancer vs. normal cells. Specificity 
is supported by lack of IF signal when cells were incubated with the mutant T26QN peptide 
(not a TG2 substrate) or in the presence of EDTA, which chelates Ca2+ (Supplementary 
Figure 1A). In addition, extracellular TG2 was detectable in the matrix deposited by AsPC1, 
BxPC3 and Panc1 cells (Supplementary Figure 2), supporting the concept that PDA cells 
secrete TG2 into the ECM.
TG2 knockdown inhibits PDA tumor growth in vivo
To proceed with functional studies, TG2 was knocked down in AsPC1 and Panc1 cells by 
stably transducing shRNA targeting TG2 (shTG2). TG2 protein and mRNA expression levels 
were significantly downregulated in shTG2 transduced cells compared to cells transduced 
with scrambled shRNA (shCtrl, Figure 1D). TG2 secretion in the CM was also decreased in 
shTG2 compared to shCtrl transduced PDA cells (Figure 1D, right panel). However, in 
vitro, no significant differences in the proliferation and ability to form clones between PDA 
cells +/−shTG2 were observed (Supplementary Figure 3), suggesting that any effects of TG2 
on tumor growth are not explained by direct effect on cancer cells.
To measure the effects of TG2 on tumor formation and progression, orthotopic pancreatic 
xenografts derived from AsPC1 and Panc1 cells in which TG2 was stably knocked down 
were used. Average tumor volume and weight were significantly decreased in xenografts 
derived from AsPC1+shTG2 compared to AsPC1+shCtrl cells (Figure 2A, left and middle 
panels). There was no significant difference in the number of macro-metastases between 
groups (Figure 2A, right panel). Stable knockdown of TG2 in AsPC1+shTG2 xenografts 
compared to controls was confirmed by IHC and was quantified by comparing H scores (see 
SM, Figure 2B). Similar decrease in average tumor volume and weight was observed in 
Panc1+shTG2 vs. Panc1+shCtrl xenografts (Figure 2C, left and middle panels). The number 
of macro-metastases was significantly decreased in Panc1+shTG2 tumor bearing mice 
compared to controls (Figure 2C, right panel). Stable knockdown of TG2 was confirmed by 
IHC (Figure 2D). Together, these data demonstrate that TG2 expression levels in PDA cells 
strongly correlate with in vivo tumor growth.
TG2 is enzymatically active and crosslinks collagen in PDA tumors
Under normal physiological conditions, TG2 is enzymatically inactive in vitro and in vivo. 
Various stressors such as injury or hypoxia, are required to activate TG2 (30). To determine 
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whether TG2 is activated in the pancreatic TME, we measured incorporation of the FITC-
labeled T26 peptide, which is specifically crosslinked to ECM proteins by TG2 (29). 
Enzymatically active TG2 was detectable both intra- and extra-cellularly in AsPC1 and 
Panc1 xenograft sections (Figure 3A), suggesting that the enzyme is active in the pancreatic 
milieu. Incubation with the T26 peptide in the presence of EDTA and with the mutant 
T26QN peptide, which is not a TG2 substrate, were used as negative controls to prove 
specificity. TG2 activity was detectable even in the absence of DTT, a known TG2 activator 
(31) (Supplementary Figure 4), supporting that the enzyme is activated in situ.
One of the known TG2 substrates is collagen 1, abundant in the pancreatic DS. PSR staining 
was used to determine whether collagen 1 was crosslinked by TG2 in the pancreatic TME. 
Birefringence of PSR staining under polarizing microscope is highly specific for collagen 
fibers, which appear red, orange, yellow, or green in order of decreasing thickness (26). 
Collagen fibers stained mostly bright orange, red, and yellow in AsPC1+shCtrl tumors, 
while fibers were mostly green and yellow in AsPC1+shTG2 tumors (Figures 3B left and 
middle panels), suggesting that collagen fibers are thicker in TG2 expressing tumors. 
Moreover, the area of birefringence corresponding to collagen was more extensive in 
AsPC1+shCtrl compared to AsPC1+shTG2 xenografts (Figure 3B, right panel), suggesting 
increased collagen deposition in TG2 expressing tumors, most collagen being deposited 
around ducts and at the edge of tumors. To verify that this correlation is relevant to human 
pancreatic tumors, PSR staining of TG2-high and TG2-low human tumors was carried out 
(n=6 per group). TG2 expression levels strongly correlated with the percentage of 
crosslinked collagen (p < 0.001, Figure 3C).
Additionally, the sircol and the hydroxyproline assays were used to measure soluble and 
total collagen, respectively, in protein extracts from xenografts expressing TG2 or not. The 
amount of soluble collagen was increased in AsPC1+shTG2 compared to AsPC1+shCtrl 
tumors (Figure 3D, left panel) and in Panc1+shTG2 compared to Panc1+shCtrl xenografts 
(Figure 3D, right panel), while total collagen content was similar (Supplementary Figure 5). 
Collectively, these data suggest that TG2 secreted from PDA cells promotes collagen 
crosslinking in the pancreatic stroma.
TG2-mediated crosslinked collagen and TG2 expressing PDA cells promote the growth 
and activation of fibroblasts
We next determined the functional significance of native and TG2-crosslinked collagen to 
the proliferation of fibroblasts and cancer cells. The proliferation of NHF544 fibroblasts was 
increased on collagen coated compared to uncoated plates (Figure 4A, left-upper panel) and 
on TG2-crosslinked collagen compared to native collagen (Figure 4A, left-lower panel), 
supporting that collagen and crosslinked collagen in the matrix promote fibroblast 
proliferation.
Next, we studied the influence of TG2 secreted by cancer cells on stromal cell proliferation. 
Direct co-culture of TG2 expressing AsPC1 cells significantly promoted GFP-labeled 
fibroblast (GFP-HNDF) proliferation over a 14-day period compared to co-culture of 
fibroblasts with AsPC1+shTG2 cells (Figure 4A, right panel). Fibroblast proliferation in co-
culture with cancer cells expressing and secreting low levels of TG2 (AsPC1+shTG2) was 
Lee et al. Page 7
Clin Cancer Res. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
not different from proliferation of fibroblast cultured alone, supporting that secretion of TG2 
in co-culture models augments the fibrotic response. However, in the absence of co-cultured 
PDA cells, addition of recombinant TG2 to the growth media did not alter fibroblast or 
stellate cell proliferation (Supplementary Figure 6), suggesting that TG2 acts in concert with 
other factors secreted in the matrix.
To measure fibroblast activation in the presence of cancer cells, expression of α-smooth 
muscle actin (α-SMA) was measured by IF. Co-culture of NHF544 cells with AsPC1 and 
Panc1 cells induced expression of αSMA (Figure 4B, left panels). To determine whether 
TG2 secreted by PDA cells contributes to fibroblast activation, NHF544 cells were co-
cultured with PDA cells +/−shTG2, and IF staining measured collagen deposition. Increased 
collagen 1 staining was observed in NHF544 fibroblasts co-cultured with AsPC1 and Panc1 
control cells, compared to fibroblasts co-cultured with AsPC1+shTG2 and Panc1+shTG2 
cells (Figure 4B, right panels). Likewise, in tumors, the number of α-SMA expressing 
(activated) myofibroblasts was increased in AsPC1+shCtrl compared to AsPC1+shTG2 
xenografts (Figure 4C). Collectively, these data show that in the pancreatic TME, TG2 
secreting PDA cells promote the growth, activation, and collagen deposition by 
myofibroblasts.
We next tested whether these stromal alterations conversely regulate the growth of PDA 
cells. Proliferation of AsPC1 and Panc1 cells was promoted when cells were cultured on 
collagen coated vs. uncoated plates (Figure 4D, upper panel) and on a feeder layer of hPSCs 
vs. uncoated plates (Figure 4D, lower panel). Taken together, these results demonstrate that 
PDA cells secreting TG2 in the tumor milieu promote fibroblast activation and proliferation 
as well as collagen crosslinking, leading to stromal alterations, which in turn promote tumor 
growth.
Matrix induced YAP/TAZ activation promotes PDA cell proliferation
As the pancreatic stroma becomes infiltrated by collagen and fibroblasts, its stiffness 
increases (32). One of the mechanisms activated by the physical properties of the ECM is 
the YAP/TAZ pathway (33), which regulates cancer cell growth. We measured activation of 
the pathway by IF staining for the two nuclear factors in PDA cells plated on collagen vs. 
uncoated plates. Increased nuclear YAP/TAZ staining was observed in Panc1 and AsPC1 
cells on collagen (Figure 5A). Western blotting showed decreased levels of phospho-YAP 
(p-Yap, inactive) and increased ratio of total-YAP/p-YAP were recorded in PDA cells plated 
on collagen-coated vs. uncoated plates (Figure 5A, right panel), indicating YAP activation 
by the collagen matrix.
Next, IF staining determined the effect of TG2 on YAP/TAZ activation in PDA cells. 
Increased nuclear localization was recorded in TG2 expressing control Panc1 and AsPC1 
cells compared to PDA cells transduced with shTG2 (Figure 5B). Decreased level of p-YAP 
and increased ratio of total-YAP/p-YAP were observed in Panc1+shCtrl compared to 
Panc1+shTG2 cells (Figure 5B, right panel). We next measured the transcriptional activity 
of YAP in Panc1 cells plated on collagen by using the TEAD4 reporter assay and by 
measuring the mRNA levels for CTGF, a known YAP/TAZ target gene. TEAD4 activity 
(Figure 5C, upper panel) and CTGF mRNA levels (Figure 5C, lower panel) were increased 
Lee et al. Page 8
Clin Cancer Res. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
in Panc1+shCtrl compared to Panc1+shTG2 cells, confirming activation of the pathway in 
TG2 expressing cells.
To determine the significance of YAP/TAZ to PDA cell proliferation, transient siRNA 
transfection targeting both transcription factors was employed. YAP and TAZ knockdown 
by siRNA confirmed by western blotting (Figure 5D, upper panel) caused decreased 
proliferation of AsPC1 and Panc1 cells grown on collagen (Figure 5D, lower panel). 
Collectively, these data suggest that the transcription factors YAP and TAZ are activated in 
TG2 expressing PDA cells and outline a new mechanism by which cancer cell proliferation 
is modulated by TG2 through signals reflected from the tumor into the surrounding stroma 
(Figure 6).
Discussion
Our findings outline how changes in the pancreatic cancer stroma induced by TG2 secreted 
from PDA cells alter tumor growth. While overexpression of TG2 in epithelial cancers (34, 
35) including in pancreatic cancer (36, 37) has been previously reported, and its direct 
effects on cellular oncogenic signaling have been dissected (37, 38), this is the first report 
describing the effects of TG2 on the pancreatic TME, and its subsequent consequences on 
cancer cell proliferation and tumor growth. We demonstrate that TG2 expressing PDA cells 
form larger pancreatic tumors, enriched in thick collagen fibers and in myofibroblasts. The 
dense stroma of TG2 expressing tumors conveys signals leading to YAP/TAZ activation in 
cancer cells promoting cell proliferation and tumor growth. This report has several important 
consequences.
First, we demonstrate that TG2 knockdown in pancreatic cancer cells inhibited tumor 
growth. This effect was more pronounced in Panc1 compared to AsPC1 cells, possibly 
because of the shorter doubling times of Panc1 cells, which are more aggressive and semi-
mesenchymal. Interestingly, the smaller tumor volumes were not accounted for by decreased 
proliferation or clonogenic potential of the PDA cells, but by substantial stromal alterations. 
A previous study using siRNA targeting TG2 delivered as liposomes into the peritoneal 
cavity noted inhibition of pancreatic tumor growth along with decreased tumor vascularity 
and decreased cancer cell proliferation (36). In that study, TG2 knockdown affected all TG2 
expressing cells exposed to the carrier liposomes. It is, therefore, possible that TG2 
knockdown in endothelial cells led to the anti-angiogenic effect reported there and the 
subsequent inhibition of cell proliferation (36). Contrasting to that study and consistent with 
TG2 knockdown restricted to PDA cells in our model, we did not observe changes in multi-
vessel density between tumors expressing TG2 or not (not shown). However, we report a 
significant decrease in the number of activated myofibroblasts and thick collagen fibers in 
tumors derived from shTG2 transduces cells. We show that these stromal alterations directly 
affect proliferation of fibroblasts and cancer cells. The protective role of the pancreatic 
stroma to cancer cells has been previously recognized and linked to the resistance of 
pancreatic tumors to chemo and radiotherapy (39–41). Our data implicate for the first time 
TG2 as a modulator of the pancreatic TME through its protein crosslinking properties.
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Second, we report that TG2 is enzymatically active in PDA cells and in the matrix where it 
crosslinks collagen, and possibly other ECM substrates. It is known that the functions of 
TG2 are tightly controlled by environmental factors, which cause allosteric structural 
changes and alter the accessibility of the catalytic site. High Ca2+ concentrations in the ECM 
allow the protein to adopt an open conformation that exposes the enzymatic core, while high 
intracellular GTP forces a closed, enzymatically inactive structure (19). It is, therefore, 
accepted that TG2 is enzymatically inactive in the intracellular environment, under normal 
physiological conditions, as we have also observed here by analyzing human fibroblasts and 
mesothelial LP9 cells. However, crosslinking activity was detectable in PDA cells and their 
matrix as assessed in vitro and in vivo, suggesting that the enzyme is activated in 
transformed cells and in the pancreatic matrix. While the factors causing TG2 activation in 
this context remain unknown, it is tempting to speculate that hypoxia or other types of tissue 
injury inflicted by tumorigenesis may be inducing transglutaminase activity in vivo (30, 42). 
The involvement of metabolic or physical factors that could be expressed or function 
differently in transformed vs. normal cells (e.g. oxidative stress, calcium homeostasis) 
cannot be excluded. Interestingly, a previous report suggested that Ikβα, the NF-κB 
inhibitory subunit, is a direct substrate of TG2 in PDA cells (16), although direct evidence of 
TGase activity was not provided.
We also show that collagen 1 was crosslinked by TG2 in the pancreatic milieu leading to 
formation of a dense matrix that stimulated the growth of fibroblasts and cancer cells. 
Increased collagen deposition was noted in fibroblasts co-cultured with TG2 expressing 
PDA cells. Our findings are consistent with a previous report demonstrating that collagen 
crosslinked by TG2 stimulated the proliferation of dermal fibroblasts (25) and with studies 
demonstrating the involvement of TG2 in wound healing and in pathologic fibrotic 
responses in the lung or liver (15, 43–46). We suspect that the enzyme has other substrates 
in the pancreatic ECM and that their modifications through crosslinking could contribute to 
the distinct architecture of the DS, which in turn fosters tumor progression.
Third, we link here for the first time TG2 to activation of the transcriptional regulators, YAP 
and TAZ, in cancer cells. This pathway, strongly implicated in cell survival and proliferation 
and activated in epithelial cancers (47, 48), is known to be regulated by the physical 
properties of the ECM and to translate mechanical cues into relevant biological signals (33). 
Recent reports have implicated YAP signaling in pancreatic tumor progression downstream 
of mutant Ras or independent of it (49, 50). We propose that the pancreatic matrix rendered 
denser by TG2 through collagen crosslinking and stimulation of a fibrotic response, provides 
positive proliferative feedback to the cancer cells by stimulating YAP/TAZ signaling. 
Interestingly, TG2 expression levels did not alter cancer cell proliferation in the absence of 
the matrix. However, we cannot exclude that signals other than tissue stiffness, directly 
modulated by TG2 or by the matrix, contribute to YAP activation in this context.
These observations led us to posit that the stimulatory growth signals conveyed by TG2 
require the stroma, which “deflects” mechanical or biological cues from the tumor milieu 
into an active oncogenic program. In all, our findings support the involvement of 
enzymatically active TG2 in the progression of PDA and future studies targeting the 
crosslinking activity of TG2 to disrupt tumor progression.
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Translational Relevance
Aggressive and chemotherapy-resistant pancreatic cancer is commonly associated with a 
dense stroma, which forms a protective niche for cancer cells. We hypothesized that 
tissue transglutaminase (TG2), a transamidating enzyme secreted by pancreatic cancer 
cells, promotes pancreatic cancer progression by protein crosslinking in the stroma. Our 
data present the first evidence that TG2 is abundantly secreted and enzymatically active 
in the pancreatic tumor milieu where it crosslinks collagen and stimulates fibroblast 
proliferation. We demonstrate that TG2 orchestrates the development of a characteristic 
fibrotic inflammatory reaction that enables tumor growth. Our data point to a novel 
mechanism, involving the tumor microenvironment by which TG2 promotes pancreatic 
tumor progression. The findings have important consequences for developing strategies 
to block TG2 enzymatic activity and control pancreatic cancer growth.
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Figure 1. TG2 is expressed and active in pancreatic cancer cells and tumors
(A) Immunostaining for TG2 in normal pancreas (left panels, upper; 40×, lower; 200×); 
immunostaining for TG2 (upper right) and isopeptide (lower right) in PDA specimens 
(200×). (B) Western blotting for TG2 in PDA, HPNE, stellate (hPSC) cells and NHF544 
fibroblasts (left) and in CM (right, 40 μl/lane) collected from PDA cells. (C) IF for TG2 
(AlexaFluor® 488, green) and 5-BP (Streptavidin, Alexa Fluor® 647, red) in AsPC1, Panc1 
and NHF544 cells (600×). Nuclei are visualized by DAPI. (D) TG2 expression measured by 
RT-PCR (left) and western blotting (middle and right) in AsPC1 and Panc1 cells stably 
transduced with shRNA targeting TG2 (shTG2) or control shRNA (shCtrl).
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Figure 2. TG2 knockdown inhibits tumor growth in an orthotopic pancreatic xenograft mouse 
model
(A) Average tumor volume (left, p = 0.02), weight (middle, p = 0.04), and number of 
metastases (right, p = 0.70) of xenografts derived from AsPC1 cells transduced with TG2 or 
control shRNA (shCtrl; n=11, shTG2; n=12). (B) IHC for TG2 in AsPC1+shCtrl and 
AsPC1+shTG2 xenografts (left, 100×). H scores quantitated TG2 expression in tumors 
(right, n=10 per group, p = 0.004). (C) Average tumor volume (left, p = 0.01), weight 
(middle, p = 0.006), and number of metastases (right, p = 0.03) derived from Panc1+shTG2 
or +shCtrl cells (n=7 per group). (D) IHC for TG2 in Panc1+shCtrl and PanC1+shTG2 
xenografts (left, 100×). H scores quantitated TG2 expression in tumors (right, n=3 per 
group, p = 0.007). Bars represent average measurements +/− SE; * p < 0.05.
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Figure 3. TG2 is enzymatically active and crosslinks collagen in the PDA stroma
(A) IF using FITC-labeled T26, T26 and EDTA (negative control), and T26QN (negative 
control) in AsPC1 and Panc1 xenografts (200×). (B) PSR staining determines deposition and 
thickness of collagen fibers in AsPC1+shCtrl and AsPC1+shTG2 tumors; upper - bright 
field transmission (BFT) microscopy, lower - polarizing light microscopy (200×, left). 
Quantification of collagen fiber thicknesses based on differences in birefringence (middle) 
and quantitative assessment of collagen content based on area staining for collagen per field 
(right, n=11 per group, p = 0.001. (C) PSR staining measures deposition and thickness of 
collagen fibers in TG2 high and low human tumors; upper–IHC for TG2 (100×), lower–
polarizing light microscopy, (200×, left). Quantification of collagen fiber thicknesses based 
on differences in birefringence (middle) and quantitative assessment of collagen content 
based on area staining for collagen per field (right, n=6 per group). Bars represent fold 
changes +/− standard error (SE), p < 0.0001. (D) Soluble collagen measured by the Sircol 
assay in AsPC1+/− shTG2 (left, n=6 per group, p = 0.001) and Panc1+/−shTG2 tumors 
(right, n=6 per group, p = 0.005). Bars represent average measurements +/− SE; * p < 0.05.
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Figure 4. TG2 promotes fibrosis in the PDA stroma
(A) Proliferation of NHF544 cultured on collagen coated or uncoated plates (left, upper, p < 
0.04) and on native or TG2-crosslinked collagen (left, lower, p < 0.03). Proliferation of 
GFP-HNDF in co-culture with AsPC1+shCtrl or AsPC1+shTG2 cells or grown alone for 14 
days (right, p < 0.03). (B) IF for α-SMA (left panels, Alexa Fluor® 488, green) in NHF544 
cultured alone (left) or co-cultured with AsPC1 (middle) or Panc1 cells (right). Nuclei are 
visualized by DAPI. IF for collagen 1 (right panels, Cy5, red) of NHF544 co-cultured with 
AsPC1+shCtrl or AsPC1+shTG2 (left) or with Panc1+shCtrl and Panc1+shTG2 cells (right). 
(C) IHC for α-SMA identifies myofibroblasts in AsPC1+shCtrl and AsPC1+shTG2 
xenografts (upper, 100×). H scores quantify fibrosis (lower, shCtrl; n=10, shTG2; n=7, p < 
0.05). (D) Proliferation of AsPC1 and Panc1 cells on collagen coated or uncoated plates 
(upper, p < 0.03), and on uncoated plates or a feeder layer of hPSCs (lower, p < 0.006). (A, 
D): bars represent average of 4 replicate measurements for the groups +/− SE; * p < 0.05.
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Figure 5. TG2 and collagen activate YAP/TAZ in PDA cells
(A) IF for YAP/TAZ (left panels, Alexa Fluor® 488, green) in Panc1 and AsPC1 cells grown 
on collagen coated or uncoated slides (600×). Pie charts (right, upper) show percentage of 
nuclear YAP/TAZ, and western blotting (right, lower) shows total- and p-YAP in Panc1 and 
AsPC1 cells plated on collagen or uncoated plates. Bars represent the ratio of total-YAP/p-
YAP. (B) IF for YAP/TAZ (left panels, Alexa Fluor® 488, green) in Panc1+shCtrl or 
Panc1+shTG2 and AsPC1+shCtrl or AsPC1+shTG2 cells grown on collagen (600×). Pie 
charts (right, upper) show the percentage of nuclear YAP/TAZ, and western blotting (right, 
lower) shows total- and p-YAP in Panc1+shCtrl or Panc1+shTG2 grown on collagen. Bars 
represent the ratio of total-YAP/p-YAP. (C) TEAD4 reporter assay in Panc1+shCtrl or 
Panc1+shTG2 grown on collagen (upper, n=5, p = 0.009). Luciferase activity was 
normalized to renilla. Bars represent averages of 5 replicates/group +/− SE; * p < 0.05. Q-
RT-PCR measures CTGF mRNA levels in Panc1+shCtrl or Panc1+shTG2 grown on 
collagen (lower, p = 0.04). (D) Western blotting for YAP and TAZ in AsPC1 and Panc1 
cells transfected with siRNA targeting YAP and TAZ (upper). Proliferation of AsPC1 
(lower, left) and Panc1 (lower, right) cells transfected with siRNA targeting YAP and TAZ 
(n=4 per group, p < 0.01). Bars represent average of 4 replicates +/− SE; * p < 0.05.
Lee et al. Page 20
Clin Cancer Res. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. 
Proposed mechanism by which TG2 promotes tumor growth.
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